Results 41 to 50 of about 11,617 (148)
Frontiers in PharmacologyBackgroundThis study aimed to evaluate the aflibercept biosimilars compared to the reference product aflibercept (Eylea®) in terms of efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).MethodsWe ...
Yating Zhou +3 more
doaj +1 more source
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background and Aims Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of tumor burden and minimal residual disease. As total neoadjuvant therapy (TNT) increasingly supports organ‐preserving strategies in locally advanced rectal cancer (LARC), reliable markers of treatment response are needed.
Faizan Bashir +4 more
wiley +1 more source
MedComm, Volume 7, Issue 7, July 2026.Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu +7 more
wiley +1 more source
Molecular Therapy: Methods & Clinical DevelopmentIxoberogene soroparvovec (ixo-vec), formerly ADVM-022, is an adeno-associated virus (AAV) gene therapy using the AAV.7m8 capsid for intravitreal delivery (IVT) to transduce retinal tissue and produce sustained intraocular aflibercept for treating ...
Kris Poulsen +7 more
doaj +1 more source
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.ABSTRACT Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases.
Sébastien Bihorel +10 more
wiley +1 more source
Effect of aflibercept combined with triamcinolone acetonide on aqueous humor growth factor and inflammatory mediators in diabetic macular edema [PDF]
International Journal of OphthalmologyAIM: To investigate the efficacy of aflibercept combined with sub-tenon injection of triamcinolone acetonide (TA) in treating diabetic macular edema (DME) and to examine changes in growth factors and inflammatory mediator levels in aqueous humor after ...
De-Shuang Li +3 more
doaj +1 more source
Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies
Advanced Healthcare Materials, Volume 15, Issue 23, 19 June 2026.Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best +5 more
wiley +1 more source
International Medical Case Reports Journal, 2018 Olga E Makri, Foteini N Tsapardoni, Panagiotis Plotas, Athina Pallikari, Constantine D Georgakopoulos Department of Ophthalmology, University of Patras, Patras, Greece Purpose: To report the 12-month outcomes of a patient switching from intravitreal ...
Makri OE +4 more
doaj
Cancer Medicine, Volume 15, Issue 6, June 2026.ABSTRACT Background Since real‐world data lack information on treatment assignment (usually the only information available is treatment prescription/administration) and early outcomes can happen in advanced cancer, some design choices may introduce immortal time due to selection or due to treatment strategy misclassification.
Xabier Garcia‐Albeniz +22 more
wiley +1 more source
BMC OphthalmologyBackground To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.
Nozomu Hashiya +5 more
doaj +1 more source